JP2022050618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022050618A5 JP2022050618A5 JP2022004089A JP2022004089A JP2022050618A5 JP 2022050618 A5 JP2022050618 A5 JP 2022050618A5 JP 2022004089 A JP2022004089 A JP 2022004089A JP 2022004089 A JP2022004089 A JP 2022004089A JP 2022050618 A5 JP2022050618 A5 JP 2022050618A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- antibody
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 239000003112 inhibitor Substances 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 11
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 229940121827 Hedgehog pathway inhibitor Drugs 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 230000004614 tumor growth Effects 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 230000001394 metastastic effect Effects 0.000 claims 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 230000009467 reduction Effects 0.000 claims 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 238000011394 anticancer treatment Methods 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 229940126634 CD38 inhibitor Drugs 0.000 claims 1
- VJQALSOBHVEJQM-UHFFFAOYSA-N COCCOC1CCC(CC1)Nc1cc(=O)n(C)c2ccc(cc12)-c1cncs1 Chemical compound COCCOC1CCC(CC1)Nc1cc(=O)n(C)c2ccc(cc12)-c1cncs1 VJQALSOBHVEJQM-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 241000289669 Erinaceus europaeus Species 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000011498 curative surgery Methods 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 230000008472 epithelial growth Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 229960005325 sonidegib Drugs 0.000 claims 1
- VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 229960004449 vismodegib Drugs 0.000 claims 1
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical group ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023112057A JP7624033B2 (ja) | 2016-05-13 | 2023-07-07 | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 |
Applications Claiming Priority (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662335743P | 2016-05-13 | 2016-05-13 | |
| US62/335,743 | 2016-05-13 | ||
| US201662340142P | 2016-05-23 | 2016-05-23 | |
| US62/340,142 | 2016-05-23 | ||
| US201662348546P | 2016-06-10 | 2016-06-10 | |
| US62/348,546 | 2016-06-10 | ||
| US201662350305P | 2016-06-15 | 2016-06-15 | |
| US62/350,305 | 2016-06-15 | ||
| US201662364920P | 2016-07-21 | 2016-07-21 | |
| US62/364,920 | 2016-07-21 | ||
| US201662374020P | 2016-08-12 | 2016-08-12 | |
| US62/374,020 | 2016-08-12 | ||
| US201762451274P | 2017-01-27 | 2017-01-27 | |
| US62/451,274 | 2017-01-27 | ||
| PCT/US2017/032408 WO2017197263A1 (en) | 2016-05-13 | 2017-05-12 | Methods of treating skin cancer by administering a pd-1 inhibitor |
| JP2018559739A JP7054680B2 (ja) | 2016-05-13 | 2017-05-12 | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559739A Division JP7054680B2 (ja) | 2016-05-13 | 2017-05-12 | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023112057A Division JP7624033B2 (ja) | 2016-05-13 | 2023-07-07 | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022050618A JP2022050618A (ja) | 2022-03-30 |
| JP2022050618A5 true JP2022050618A5 (enExample) | 2022-07-04 |
| JP7313493B2 JP7313493B2 (ja) | 2023-07-24 |
Family
ID=58800911
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559739A Active JP7054680B2 (ja) | 2016-05-13 | 2017-05-12 | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 |
| JP2018559738A Active JP6999577B2 (ja) | 2016-05-13 | 2017-05-12 | がんを処置するための抗ｐｄ－１抗体と放射線の組合せ |
| JP2022004089A Active JP7313493B2 (ja) | 2016-05-13 | 2022-01-14 | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 |
| JP2023112057A Active JP7624033B2 (ja) | 2016-05-13 | 2023-07-07 | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559739A Active JP7054680B2 (ja) | 2016-05-13 | 2017-05-12 | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 |
| JP2018559738A Active JP6999577B2 (ja) | 2016-05-13 | 2017-05-12 | がんを処置するための抗ｐｄ－１抗体と放射線の組合せ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023112057A Active JP7624033B2 (ja) | 2016-05-13 | 2023-07-07 | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 |
Country Status (32)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| WO2019143607A1 (en) * | 2018-01-16 | 2019-07-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
| US12358984B2 (en) | 2018-02-13 | 2025-07-15 | Merck Sharp & Dohme Llc | Methods for treating cancer with anti-PD-1 antibodies |
| CN112513297B (zh) | 2018-03-28 | 2024-10-22 | 得克萨斯州大学系统董事会 | 鉴定从外排体分离的dna中的表观遗传改变 |
| CN111821434A (zh) * | 2019-04-17 | 2020-10-27 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 |
| AU2019263850A1 (en) * | 2018-05-03 | 2020-11-19 | Shanghai Epimab Biotherapeutics Co., Ltd. | High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom |
| TWI890661B (zh) * | 2018-06-21 | 2025-07-21 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法 |
| JP7466519B2 (ja) | 2018-07-23 | 2024-04-12 | ガーダント ヘルス， インコーポレイテッド | 腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム |
| AU2019328344B2 (en) | 2018-08-31 | 2025-06-12 | Guardant Health, Inc. | Microsatellite instability detection in cell-free DNA |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN113015529A (zh) * | 2018-10-19 | 2021-06-22 | 生华生物科技股份有限公司 | 用于癌症治疗的免疫调节的组合 |
| EP3873500A4 (en) | 2018-10-31 | 2023-01-11 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| US12257286B2 (en) | 2018-10-31 | 2025-03-25 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| HRP20240825T1 (hr) | 2018-11-14 | 2024-09-27 | Regeneron Pharmaceuticals, Inc. | Intralezijsko davanje pd-1 inhibitora za liječenje raka kože |
| AU2019379325B2 (en) * | 2018-11-16 | 2025-04-24 | Genexine, Inc. | Method of treating a tumor with a combination of IL-7 protein and an immune checkpoint inhibitor |
| BR112021010670A2 (pt) * | 2018-12-03 | 2021-08-24 | Fusion Pharmaceuticals Inc. | Terapia de combinação de radioimunoconjugado e inibidor de danos e reparo do dna |
| WO2020118216A1 (en) * | 2018-12-08 | 2020-06-11 | Board Of Regents, The University Of Texas System | Identification and targeting of tumor promoting carcinoma associated fibroblasts for diagnosis and treatment of cancer and other diseases |
| WO2020123388A1 (en) | 2018-12-11 | 2020-06-18 | Board Of Regents, The University Of Texas System | Radiotherapies and uses thereof |
| KR20210119451A (ko) * | 2019-01-21 | 2021-10-05 | 사노피 | 진행성 단계의 고형 종양 암에 대한 치료용 rna |
| CN113365659B (zh) * | 2019-01-31 | 2023-08-18 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体治疗头颈癌的用途 |
| AU2020228296B2 (en) | 2019-02-28 | 2025-10-02 | Regeneron Pharmaceuticals, Inc. | Administration of PD-1 inhibitors for treating skin cancer |
| CA3138459A1 (en) | 2019-04-28 | 2020-11-05 | Institut Pasteur De Montevideo | Ionic channel modulation as a method for treating tumors through inflammasome activation |
| CN120939219A (zh) * | 2019-05-13 | 2025-11-14 | 瑞泽恩制药公司 | 用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合 |
| US20210169979A1 (en) * | 2019-12-05 | 2021-06-10 | The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges | System and method for sonosensitized cancer immunotherapy with nanoparticles |
| KR102195221B1 (ko) * | 2019-12-31 | 2020-12-24 | 서울대학교산학협력단 | 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물 |
| WO2021154746A1 (en) | 2020-01-28 | 2021-08-05 | Reflexion Medical, Inc. | Joint optimization of radionuclide and external beam radiotherapy |
| CN113318226A (zh) * | 2020-02-28 | 2021-08-31 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体联合放射性射线治疗肺癌的方法 |
| CN111840585B (zh) * | 2020-07-20 | 2022-05-03 | 厦门大学 | 一种用于肿瘤免疫治疗的药物组合 |
| EP4204592A1 (en) * | 2020-08-26 | 2023-07-05 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer by administering a pd-1 inhibitor |
| EP4208258A1 (en) * | 2020-09-03 | 2023-07-12 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer pain by administering a pd-1 inhibitor |
| EP4291581A1 (en) * | 2021-02-11 | 2023-12-20 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer by administering a neoadjuvant pd-1 inhibitor |
| CN115125211A (zh) * | 2021-03-24 | 2022-09-30 | 核工业总医院 | 免疫治疗疗效评价用结肠癌腹膜转移小鼠模型 |
| CN113368226B (zh) * | 2021-06-30 | 2021-11-30 | 上海力沃生物科技有限公司 | 含有dc瘤苗的药物组合物及其在治疗癌症中的应用 |
| WO2023014206A1 (ko) * | 2021-08-06 | 2023-02-09 | 알지노믹스 주식회사 | 방사선 치료와 병용되는 유전자 치료제로서 암 특이적 트랜스-스플라이싱 리보자임 |
| WO2023154796A2 (en) * | 2022-02-09 | 2023-08-17 | Dragonfly Therapeutics, Inc. | Pharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16 |
| WO2024165454A1 (en) * | 2023-02-06 | 2024-08-15 | F. Hoffmann-La Roche Ag | Combination therapy and uses thereof |
| WO2025040080A1 (en) * | 2023-08-21 | 2025-02-27 | Beigene Switzerland Gmbh | Treatment of esophageal cancer with anti-lag3, anti-pd-1 and chemotherapy |
| WO2025117889A2 (en) * | 2023-11-30 | 2025-06-05 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer by administering a combination therapy including a neoadjuvant pd-1 inhibitor |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| MXPA02001877A (es) | 1999-08-23 | 2002-08-20 | Dana Farber Cancer Inst Inc | Pd-1, un receptor para b7-4, y usos del mismo. |
| NZ530583A (en) | 1999-08-23 | 2005-10-28 | Dana Farber Cancer Inst Inc | Novel B7-4 molecules and uses therefor |
| EP3225632B1 (en) | 1999-11-30 | 2020-05-06 | Mayo Foundation for Medical Education and Research | Antibodies binding to b7-h1, a novel immunoregulatory molecule |
| AU2001273096B8 (en) | 2000-06-28 | 2005-10-13 | Dana-Farber Cancer Institute, Inc. | PD-L2 molecules: novel PD-1 ligands and uses therefor |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| WO2002086083A2 (en) | 2001-04-20 | 2002-10-31 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| JP4488740B2 (ja) | 2001-11-13 | 2010-06-23 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 免疫細胞活性化を調節する作用剤およびその使用方法 |
| WO2004004771A1 (ja) | 2002-07-03 | 2004-01-15 | Ono Pharmaceutical Co., Ltd. | 免疫賦活組成物 |
| JP2004104681A (ja) | 2002-09-12 | 2004-04-02 | Renesas Technology Corp | 入力バッファ回路 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| MXPA05006828A (es) | 2002-12-23 | 2005-09-08 | Wyeth Corp | Anticuerpos contra pd-1, y sus usos. |
| EP2270051B1 (en) | 2003-01-23 | 2019-05-15 | Ono Pharmaceutical Co., Ltd. | Antibody specific for human PD-1 and CD3 |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| ES2403055T3 (es) | 2004-04-13 | 2013-05-13 | F. Hoffmann-La Roche Ag | Anticuerpos anti-P-selectina |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| JP4361545B2 (ja) | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| JP4663394B2 (ja) | 2005-05-11 | 2011-04-06 | ダイセルポリマー株式会社 | 難めっき性被覆剤及びめっきの前処理方法 |
| EP1899379B1 (en) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Cd19 antibodies and their uses |
| HRP20151102T1 (xx) | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| US8216996B2 (en) | 2006-03-03 | 2012-07-10 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of cell surface functional molecule |
| WO2007143168A2 (en) | 2006-06-02 | 2007-12-13 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| EP2195347A1 (en) | 2007-08-17 | 2010-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating and diagnosing hematologic malignancies |
| WO2009030285A1 (en) | 2007-09-07 | 2009-03-12 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| CA2715166C (en) | 2008-02-11 | 2017-05-16 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| EP2342228B1 (en) | 2008-09-12 | 2017-09-06 | Oxford University Innovation Limited | Pd-1 specific antibodies and uses thereof |
| EP2342229A1 (en) | 2008-09-12 | 2011-07-13 | ISIS Innovation Limited | Pd-1 specific antibodies and uses thereof |
| AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| KR20250091300A (ko) | 2008-12-09 | 2025-06-20 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| MY199658A (en) | 2009-06-26 | 2023-11-14 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| CN103951753B (zh) | 2009-09-03 | 2018-01-12 | 默沙东公司 | 抗‑gitr抗体 |
| AU2010303149B2 (en) | 2009-09-30 | 2016-08-04 | Board Of Regents, The University Of Texas System | Combination immunotherapy for the treatment of cancer |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| DK2504364T3 (da) | 2009-11-24 | 2017-11-06 | Medimmune Ltd | Målrettede bindemidler mod b7-h1 |
| ME02288B (me) | 2010-02-08 | 2016-02-20 | Regeneron Pharma | Miš sa zajedničkim lakim lancem |
| CA2791930A1 (en) | 2010-03-11 | 2011-09-15 | Kerry Louise Tyson | Pd-1 antibody |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| EP2638061B1 (en) | 2010-11-11 | 2015-04-22 | The University of Hong Kong | Soluble pd-1 variants, fusion constructs, and uses thereof |
| MX338353B (es) | 2011-04-20 | 2016-04-13 | Medimmune Llc | Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1. |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| AR087405A1 (es) | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| SMT202000561T1 (it) | 2011-11-28 | 2021-01-05 | Merck Patent Gmbh | Anticorpi anti-pd-l1 e usi relativi |
| GB201120527D0 (en) | 2011-11-29 | 2012-01-11 | Ucl Business Plc | Method |
| WO2013112986A1 (en) | 2012-01-27 | 2013-08-01 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
| CA2871751C (en) | 2012-05-04 | 2021-08-24 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| US20130303250A1 (en) | 2012-05-11 | 2013-11-14 | Ryan Moore | Method of Playing a Card Game |
| SG10201700698WA (en) | 2012-05-15 | 2017-02-27 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| RU2689760C2 (ru) | 2012-05-31 | 2019-05-30 | Дженентек, Инк. | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов |
| EP3626309B1 (en) * | 2012-08-13 | 2023-03-08 | The Rockefeller University | Lxrbeta agonist for the treatment of cancer |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| EP2904011B1 (en) | 2012-10-02 | 2017-08-23 | Bristol-Myers Squibb Company | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| WO2014066834A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| JP6456305B2 (ja) | 2013-02-22 | 2019-01-23 | キュアバック アーゲー | ワクチン接種とｐｄ−１経路の阻害との組み合わせ |
| WO2014159562A1 (en) | 2013-03-14 | 2014-10-02 | Bristol-Myers Squibb Company | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use |
| KR102389677B1 (ko) | 2013-03-15 | 2022-04-21 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| MY183503A (en) | 2013-07-16 | 2021-02-23 | Genentech Inc | Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| MX2016000750A (es) | 2013-08-02 | 2016-08-05 | Aduro Biotech Holdings Europe B V | Combinacion de agonistas de cd27 e inhibicion del punto de control inmunologico para estimulacion del sistema inmunologico. |
| EP3035964B1 (en) | 2013-08-20 | 2020-09-23 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| DK3508502T5 (da) | 2013-09-20 | 2024-09-02 | Bristol Myers Squibb Co | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| PT3049441T (pt) | 2013-09-27 | 2020-01-21 | Hoffmann La Roche | Formulações de anticorpos anti-pdl1 |
| US10241115B2 (en) | 2013-12-10 | 2019-03-26 | Merck Sharp & Dohme Corp. | Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue |
| CA3131724A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| US20150190506A1 (en) * | 2013-12-17 | 2015-07-09 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| KR20170003692A (ko) | 2014-05-15 | 2017-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료 |
| PH12016502345B1 (en) | 2014-05-28 | 2023-03-01 | Agenus Inc | Anti-gitr antibodies and methods of use thereof |
| ES2901705T3 (es) | 2014-06-06 | 2022-03-23 | Bristol Myers Squibb Co | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| US10390522B2 (en) | 2014-06-19 | 2019-08-27 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| US9988452B2 (en) | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
| AU2015338974B2 (en) * | 2014-10-31 | 2021-08-26 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| EP3254110B1 (en) | 2015-02-03 | 2020-03-18 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
| SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| US20180155429A1 (en) | 2015-05-28 | 2018-06-07 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| HUE058293T2 (hu) | 2015-09-03 | 2022-07-28 | Ono Pharmaceutical Co | Szer immunitás erõsítésére rák ellen Allergin-1 antagonista felhasználásával |
| HUE063377T2 (hu) | 2015-12-22 | 2024-01-28 | Regeneron Pharma | Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére |
| US11434294B2 (en) | 2016-02-25 | 2022-09-06 | Cell Medica, Inc. | Binding members to PD-L1 |
| EP3548515A1 (en) | 2016-12-01 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
-
2017
- 2017-05-11 TW TW112143833A patent/TW202408578A/zh unknown
- 2017-05-11 TW TW106115562A patent/TWI755395B/zh active
- 2017-05-11 TW TW106115563A patent/TWI786044B/zh active
- 2017-05-11 TW TW111148425A patent/TWI822521B/zh active
- 2017-05-12 MX MX2018013847A patent/MX389733B/es unknown
- 2017-05-12 FI FIEP21191931.1T patent/FI3932951T3/fi active
- 2017-05-12 HR HRP20220014TT patent/HRP20220014T1/hr unknown
- 2017-05-12 RS RS20230397A patent/RS64218B1/sr unknown
- 2017-05-12 EP EP21191931.1A patent/EP3932951B1/en active Active
- 2017-05-12 CN CN201780028431.0A patent/CN109153724B/zh active Active
- 2017-05-12 JP JP2018559739A patent/JP7054680B2/ja active Active
- 2017-05-12 CN CN202310111307.8A patent/CN116098997A/zh active Pending
- 2017-05-12 MD MDE20190333T patent/MD3455258T2/ro unknown
- 2017-05-12 PL PL21191931.1T patent/PL3932951T3/pl unknown
- 2017-05-12 HR HRP20230236TT patent/HRP20230236T1/hr unknown
- 2017-05-12 SG SG10202011110PA patent/SG10202011110PA/en unknown
- 2017-05-12 IL IL318482A patent/IL318482A/en unknown
- 2017-05-12 HU HUE21191931A patent/HUE061417T2/hu unknown
- 2017-05-12 EP EP17727767.0A patent/EP3455259B1/en active Active
- 2017-05-12 SI SI201731309T patent/SI3932951T1/sl unknown
- 2017-05-12 KR KR1020187036323A patent/KR102470294B1/ko active Active
- 2017-05-12 SI SI201731342T patent/SI3455259T1/sl unknown
- 2017-05-12 MY MYPI2022006224A patent/MY208872A/en unknown
- 2017-05-12 WO PCT/US2017/032408 patent/WO2017197263A1/en not_active Ceased
- 2017-05-12 LT LTEP21191931.1T patent/LT3932951T/lt unknown
- 2017-05-12 PL PL17726759T patent/PL3455258T3/pl unknown
- 2017-05-12 JP JP2018559738A patent/JP6999577B2/ja active Active
- 2017-05-12 WO PCT/US2017/032397 patent/WO2017197259A1/en not_active Ceased
- 2017-05-12 LT LTEPPCT/US2017/032408T patent/LT3455258T/lt unknown
- 2017-05-12 ES ES17726759T patent/ES2899954T3/es active Active
- 2017-05-12 US US15/593,915 patent/US10457725B2/en active Active
- 2017-05-12 NZ NZ788452A patent/NZ788452A/en unknown
- 2017-05-12 ES ES21191931T patent/ES2938321T3/es active Active
- 2017-05-12 EP EP17726759.8A patent/EP3455258B1/en active Active
- 2017-05-12 CA CA3023985A patent/CA3023985A1/en active Pending
- 2017-05-12 HU HUE17726759A patent/HUE057781T2/hu unknown
- 2017-05-12 PL PL17727767.0T patent/PL3455259T3/pl unknown
- 2017-05-12 MY MYPI2018703920A patent/MY194085A/en unknown
- 2017-05-12 RS RS20211610A patent/RS62783B1/sr unknown
- 2017-05-12 DK DK17726759.8T patent/DK3455258T3/da active
- 2017-05-12 RS RS20230164A patent/RS64014B1/sr unknown
- 2017-05-12 ES ES17727767T patent/ES2943640T3/es active Active
- 2017-05-12 PT PT177267598T patent/PT3455258T/pt unknown
- 2017-05-12 US US15/593,897 patent/US20170327567A1/en active Pending
- 2017-05-12 SM SM20220015T patent/SMT202200015T1/it unknown
- 2017-05-12 HR HRP20230517TT patent/HRP20230517T1/hr unknown
- 2017-05-12 MX MX2018013848A patent/MX2018013848A/es unknown
- 2017-05-12 IL IL302924A patent/IL302924B2/en unknown
- 2017-05-12 FI FIEP17727767.0T patent/FI3455259T3/fi active
- 2017-05-12 KR KR1020227038606A patent/KR102595561B1/ko active Active
- 2017-05-12 HU HUE17727767A patent/HUE061874T2/hu unknown
- 2017-05-12 CN CN201780028425.5A patent/CN109153723B/zh active Active
- 2017-05-12 BR BR112018073291-5A patent/BR112018073291A2/pt not_active Application Discontinuation
- 2017-05-12 MD MDE20220619T patent/MD3932951T2/ro unknown
- 2017-05-12 CA CA3023984A patent/CA3023984A1/en active Pending
- 2017-05-12 SG SG11201809554VA patent/SG11201809554VA/en unknown
- 2017-05-12 DK DK21191931.1T patent/DK3932951T5/da active
- 2017-05-12 EP EP22203044.7A patent/EP4180459A1/en active Pending
- 2017-05-12 KR KR1020237036612A patent/KR20230152804A/ko not_active Ceased
- 2017-05-12 KR KR1020217040328A patent/KR102464774B1/ko active Active
- 2017-05-12 KR KR1020187036322A patent/KR102349056B1/ko active Active
- 2017-05-12 DK DK17727767.0T patent/DK3455259T5/da active
- 2017-05-12 PT PT211919311T patent/PT3932951T/pt unknown
- 2017-05-12 AU AU2017264955A patent/AU2017264955B2/en active Active
- 2017-05-12 IL IL262562A patent/IL262562B2/en unknown
- 2017-05-12 CN CN202310111383.9A patent/CN116407627A/zh active Pending
- 2017-05-12 SI SI201730995T patent/SI3455258T1/sl unknown
- 2017-05-12 SM SM20230070T patent/SMT202300070T1/it unknown
- 2017-05-12 PT PT177277670T patent/PT3455259T/pt unknown
- 2017-05-12 UA UAA201812344A patent/UA124151C2/uk unknown
- 2017-05-12 MD MDE20190335T patent/MD3455259T2/ro unknown
- 2017-05-12 AU AU2017264959A patent/AU2017264959B2/en active Active
-
2018
- 2018-10-23 ZA ZA2018/07050A patent/ZA201807050B/en unknown
- 2018-10-23 ZA ZA2018/07051A patent/ZA201807051B/en unknown
- 2018-10-24 PH PH12018502263A patent/PH12018502263A1/en unknown
- 2018-10-24 IL IL262561A patent/IL262561B/en unknown
- 2018-11-12 MX MX2022001120A patent/MX2022001120A/es unknown
- 2018-11-12 MX MX2022001123A patent/MX2022001123A/es unknown
- 2018-11-12 CL CL2018003207A patent/CL2018003207A1/es unknown
-
2019
- 2019-09-03 US US16/559,159 patent/US11505600B2/en active Active
-
2022
- 2022-01-10 CY CY20221100022T patent/CY1124901T1/el unknown
- 2022-01-14 JP JP2022004089A patent/JP7313493B2/ja active Active
- 2022-10-14 US US18/046,576 patent/US20230227542A1/en active Pending
-
2023
- 2023-07-07 JP JP2023112057A patent/JP7624033B2/ja active Active
-
2024
- 2024-09-24 AU AU2024220021A patent/AU2024220021A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022050618A5 (enExample) | ||
| JP2019515008A5 (enExample) | ||
| HRP20220014T1 (hr) | Postupci liječenja raka kože davanjem inhibitora pd-1 | |
| US12054557B2 (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer | |
| JP2022078265A5 (enExample) | ||
| JP2019519499A5 (enExample) | ||
| JP2021155431A5 (enExample) | ||
| US20180085456A1 (en) | Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy | |
| IL321717A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| JP2020508317A5 (enExample) | ||
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| JP2019503363A (ja) | 急性リンパ芽球性白血病を治療するための二重特異性の抗ｃｄ２０／抗ｃｄ３抗体 | |
| CA3129963A1 (en) | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer | |
| JPWO2019246356A5 (enExample) | ||
| TW202104263A (zh) | 雙特異性CD123xCD3雙抗體在血液系統惡性腫瘤治療中的給藥方案 | |
| JPWO2020232019A5 (enExample) | ||
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| US20210277135A1 (en) | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor | |
| JPWO2023031403A5 (enExample) | ||
| JP2023544164A (ja) | サイトカイン放出症候群の低減を伴うがんを治療するための抗体の組合せ | |
| KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도 | |
| RU2024117128A (ru) | СПОСОБЫ ЛЕЧЕНИЯ РАКА ПОСРЕДСТВОМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К CD3 x MUC16 И АНТИТЕЛ К CTLA-4 | |
| NZ748192B2 (en) | Methods of treating skin cancer by administering a pd-1 inhibitor | |
| JP2024542536A (ja) | 二重特異性抗ｃｄ３×ｍｕｃ１６抗体及び抗ｃｔｌａ－４抗体を用いてがんを治療するための方法 | |
| CN116615238A (zh) | 用于治疗癌症和减轻细胞因子释放综合征的抗体组合 |